LIPO Lipella Pharmaceuticals Inc.
Distress ·
A bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026.
Lipella's common stock was quoted on the OTC Pink Market under LIPO as of June 19, 2025. Nasdaq objected to securities paid to a placement agent and advisor.
The shares come from Series B and Series C preferred stock and placement agent warrants tied to its private offerings. On April 4, 2025 Lipella added an at-the-market program of up to $2,641,881.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company, incorporated in Delaware in February 2005, that develops new drugs by reformulating the active agents in existing generic drugs. Its strategy aims to combine the cost efficiencies of generic drugs with potential patent protection for its proprietary formulations, with a focus on diseases that have significant unaddressed morbidity and mortality and no approved drug therapy. The company has not yet commercialized any products. Its lead candidate, LP-10, is a reformulation of tacrolimus delivered to the bladder lumen using its metastable liposome drug delivery platform, for hemorrhagic cystitis, a complication of certain chemotherapies or pelvic radiation therapy. LP-310 is an oral liposomal tacrolimus formulation for oral lichen planus, an autoimmune oral mucosal disease, and began a Phase 2a dose-escalation trial in 2024. LP-410, an oral rinse for oral graft-versus-host disease, received orphan designation for tacrolimus in that indication on November 11, 2023. The text notes there is no FDA-approved local drug treatment for oral GVHD.
| Product or program | What it is | Stage |
|---|---|---|
| LP-10 | Tacrolimus reformulation for topical delivery to the bladder for hemorrhagic cystitis | Phase 2a; summary results reported in the first quarter of 2023 |
| LP-310 | Oral liposomal tacrolimus for oral lichen planus | Phase 2a dose-escalation trial started in 2024 |
| LP-410 | Oral liposomal tacrolimus rinse for oral graft-versus-host disease | Orphan designation granted November 11, 2023; IND approval received |
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $536,357 | $449,617 |
| Research and development | $3.6 million | $3.0 million |
| Net income (loss) | -$5.0 million | -$4.6 million |
| Cash from operations | -$4.0 million | -$3.2 million |
| Cash and equivalents | $2.2 million | $3.3 million |
Our latest story on this, dated Jun 12, 2026: "Lipella's bankruptcy court approves sale of substantially all assets". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 25, 2025: "Lipella Pharmaceuticals CEO says company will seek relisting after Nasdaq delisting". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 28, 2025: "Lipella Pharmaceuticals files to register 5,617,259 shares for resale, then sets up ATM". The story links the filing or release it is based on. Read the story.
Lipella Pharmaceuticals Inc. trades under the ticker LIPO on OTC.
Lipella Pharmaceuticals Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Lipella Pharmaceuticals Inc. is 1347242. Its filings are on SEC EDGAR.
4,620,837 shares as of 2025-11-13, per the cover page of its 10-Q filed 2025-11-14.
Our directory records Lipella Pharmaceuticals Inc. under United States.
Our directory classifies Lipella Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lipella Pharmaceuticals Inc. is US53630L2097.
aibio.space lists Lipella Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company, incorporated in Delaware in February 2005, that develops new drugs by reformulating the active agents in existing generic drugs. Its strategy aims to combine the cost efficiencies of generic drugs with potential patent protection for its proprietary formulations, with a focus on diseases that have significant unaddressed morbidity and mortality and no approved drug therapy.
LP-10: Tacrolimus reformulation for topical delivery to the bladder for hemorrhagic cystitis Stage: Phase 2a; summary results reported in the first quarter of 2023.
LP-310: Oral liposomal tacrolimus for oral lichen planus Stage: Phase 2a dose-escalation trial started in 2024.
Reported a bankruptcy filing. SEC Form 8-K (Items 1.03,9.01). Source
Reported a bankruptcy filing. SEC Form 8-K (Items 1.03). Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio